IMMUNOTHERAPY

Ultrasensitive ctDNA analysis reveals early predictive insights for immunotherapy outcomes in advanced solid tumors, enhancing patient management and survival predictions.

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising new hope for cancer treatment.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

Inaregacestat shows promising results in treating desmoid tumors, significantly improving progression-free survival and reducing tumor volume in recent trials.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

New trial data reveals IGV-001 enhances overall survival in glioblastoma patients, marking a potential breakthrough in treatment options.

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

Axi-cel shows impressive long-term efficacy in treating relapsed/refractory indolent non-Hodgkin lymphoma, with potential curative outcomes for patients.

Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.

Recent research reveals that GLP-1 receptor agonists significantly lower 5-year mortality rates in colon cancer patients, highlighting their potential in cancer treatment.

Dr. Hinrichs emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes.

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.

A novel combination therapy shows promising results in extending progression-free survival for patients with advanced pancreatic cancer, highlighting potential biomarkers for immunotherapy.

Dr. Christian S. Hinrichs discusses promising results from a phase 2 study on engineered TCR-T cell therapy for HPV-associated cancers.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

The FDA grants fast track designation to 4A10, a promising monoclonal antibody for treating relapsed acute lymphoblastic leukemia in children.

FOG-001 receives FDA fast track designation, promising new hope for desmoid tumor patients with its innovative approach to treatment.

MB-105 receives FDA RMAT designation, advancing treatment options for relapsed T-cell lymphoma and highlighting its promising clinical potential.

FDA fast-tracks alnodesertib and irinotecan for ATM-negative metastatic colorectal cancer, showing promising efficacy and safety in early trials.

The FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell lymphomas.

Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.